Rapid Therapeutic Science Laboratories, Inc.

$RTSL Market Cap: $26.5 Thousand

Research Board Inbox Deep Research Not Interested Shortlisted

Financial Snapshot

Revenue

$0.00

TTM

Gross Margin

Net Earnings

$59.56K

TTM

Current Assets

$317.9K

Q2 2023

Current Liabilities

$4.426M

Q2 2023

Current Ratio

7.18%

Q2 2023

Total Assets

$2.074M

Q2 2023

Total Liabilities

$4.813M

Q2 2023

Book Value

-$2.739M

Q2 2023

Cash

$2.160K

Q2 2023

P/E

0.4449

Nov 21, 2024 EST

Free Cash Flow

-$251.0K

TTM

Revenues

Revenue YoY Change

Revenues

Concept	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Revenue	$0.00	$530.00	$130.9K	$9.140K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	-100.0%	-99.6%	1332.39%

Expenses

Cost Of Revenues

Gross Profit

Gross Profit Margin

Gross Profit

Concept	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Revenue	$0.00	$530.00	$130.9K	$9.140K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Cost Of Revenue	$0.00	$200.00	$19.39K	$7.160K
Gross Profit	$0.00	$330.00	$111.5K	$1.980K
Gross Profit Margin		62.26%	85.19%	21.66%

Selling, General & Admin Expense

Research & Development

Depreciation, Depletion & Amortization

SGA Expense to Gross Profit Ratio

R&D To Gross Profit Ratio

DDA To Gross Profit Ratio

Operating Expenses Total

Operating Profits/Loss

Operational Expenses

Concept	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Selling, General & Admin	$1.239M	$2.115M	$2.023M	$397.5K	$169.7K	$135.7K	$21.62K	$12.02K	$12.30K	$20.00K	$10.00K
YoY Change	-41.4%	4.52%	409.04%	134.24%	25.07%	527.57%	79.87%	-2.28%	-38.5%	100.0%
% of Gross Profit		640839.39%	1814.2%	20075.25%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$23.97K	$34.60K	$82.26K	$37.50K	$0.00	$16.39K
YoY Change	-30.72%	-57.94%	119.36%		-100.0%
% of Gross Profit		10484.85%	73.76%	1893.94%
Operating Expenses	$1.263M	$2.171M	$2.106M	$435.0K	$169.7K	$152.1K	$21.62K	$12.02K	$12.30K	$20.00K	$10.00K
YoY Change	-41.8%	3.09%	384.08%	156.34%	11.58%	603.42%	79.87%	-2.28%	-38.5%	100.0%
Operating Profit	-$1.263M	-$2.170M	-$1.994M	-$433.0K
YoY Change	-41.79%	8.84%	360.53%

Interest Expenses

Interest Expenses To Operating Income %

Other Expense/Income

Interest & Other Expense/Income

Concept	2022	2021	2020	2019	2018	2017
Interest Expense	$1.896M	-$1.329M	-$58.01K	-$191.6K	-$180.5K	-$28.61K
YoY Change	-242.59%	2191.74%	-69.72%	6.12%	531.0%
% of Operating Profit
Other Income/Expense, Net	-$531.4K	$631.9K
YoY Change	-184.1%

Income/Loss

Pretax Income

Income Tax

Net Profits/Loss

Pretax Income YoY Change

Income Tax Rate

Net Profits/Loss YoY Change

Basic EPS

Net Income To Revenue Ratio

Pretax & Net Income

Concept	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Pretax Income	-$1.795M	-$2.868M	-$2.052M	-$624.6K	-$348.8K	-$2.553M	-$21.62K	-$12.02K	-$12.30K	-$20.00K	-$10.00K
YoY Change	-37.42%	39.75%	228.56%	79.04%	-86.34%	11708.09%	79.87%	-2.28%	-38.5%	100.0%
Income Tax	$0.00	$0.00	$0.00							$0.00	$0.00
% Of Pretax Income
Net Earnings	-$1.795M	-$2.868M	-$2.052M	-$624.6K	-$348.8K	-$2.553M	-$21.62K	-$12.02K	-$12.30K	-$20.00K	-$10.00K
YoY Change	-37.42%	39.75%	228.56%	79.04%	-86.34%	11708.09%	79.87%	-2.28%	-38.5%	100.0%
Net Earnings / Revenue		-541109.43%	-1567.46%	-6833.48%
Basic Earnings Per Share	-$0.23	-$0.38
Diluted Earnings Per Share	-$0.23	-$375.9K	-$304.0K	-$260.1K	-$7.243M	-$25.88M	-$199.4K	-$4.435K	-$4.539K	-$7.380K	-$4.566K

Assets & Liabilities

Cash & Short-Term Investments

Cash & Equivalents

Cash To Operating Expenses Ratio

Inventory

Receivables

Total Short-Term Assets

Property, Plant And Equipment

Long-Term Investments

Total Long-Term Assets

Total Assets

Net Income To Total Assets Percentage

Accounts Payable

Short-Term Debt

Long Term Debt Due

Total Short-Term Liabilities

Long-Term Debt

Other Long-Term Liabilities

Total Long-Term Liabilities

Total Liabilities

Short-Term To Long-Term Debt Ratio

Short-Term Assets To Debt Ratio

Long-Term Debt To Net Income Ratio

Assets & Liabilities

Concept	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012
Cash & Short-Term Investments	$0.00	$192.5K	$499.2K	$136.2K	$1.330K	$12.30K	$7.400K	$9.240K	$9.980K	$20.00K	$30.00K
YoY Change	-100.0%	-61.44%	266.43%	10142.11%	-89.19%	66.22%	-19.91%	-7.41%	-50.1%	-33.33%
Cash & Equivalents
Short-Term Investments
Other Short-Term Assets	$58.15K	$51.63K			$0.00	$10.18K	$0.00	$750.00	$750.00	$0.00	$10.00K
YoY Change	12.63%				-100.0%		-100.0%	0.0%		-100.0%
Inventory	$175.1K	$175.1K	$186.8K	$5.870K
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$233.2K	$419.2K	$686.0K	$142.1K	$1.330K	$22.48K	$7.400K	$9.990K	$10.73K	$20.00K	$40.00K
YoY Change	-44.37%	-38.89%	382.76%	10583.46%	-94.08%	203.78%	-25.93%	-6.9%	-46.35%	-50.0%
Property, Plant & Equipment	$1.851M	$1.611M	$599.5K		$0.00	$0.00
YoY Change	14.94%	168.68%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets					$0.00	$3.760K
YoY Change					-100.0%
Total Long-Term Assets	$2.021M	$1.781M	$827.0K	$302.5K	$0.00	$3.760K	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	13.51%	115.34%	173.38%		-100.0%
Total Assets	$2.255M	$2.200M	$1.513M	$444.6K	$1.330K	$26.24K	$7.400K	$9.990K	$10.73K	$20.00K	$40.00K
YoY Change
Accounts Payable	$891.4K	$465.2K	$112.3K	$64.58K	$19.65K	$14.95K	$300.00	$1.280K	$0.00	$0.00	$0.00
YoY Change	91.62%	314.25%	73.89%	228.65%	31.44%	4883.33%	-76.56%
Accrued Expenses	$223.3K	$119.0K	$354.7K	$400.7K	$209.1K	$28.61K
YoY Change	87.62%	-66.45%	-11.49%	91.6%	631.0%
Deferred Revenue
YoY Change
Short-Term Debt	$2.481M	$1.100M	$675.3K	$883.2K	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	125.63%	62.86%	-23.54%
Long-Term Debt Due	$820.6K	$283.7K	$23.35K	$23.35K	$741.0K	$645.3K	$30.00K	$10.00K
YoY Change	189.25%	1114.99%	0.0%	-96.85%	14.83%	2051.13%	200.0%
Total Short-Term Liabilities	$4.966M	$3.053M	$1.209M	$1.494M	$969.8K	$688.9K	$30.30K	$11.28K	$0.00	$0.00	$0.00
YoY Change	62.66%	152.54%	-19.07%	54.03%	40.78%	2173.56%	168.62%
Long-Term Debt	$150.0K	$150.0K	$315.2K	$315.2K	$2.200M	$2.200M	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	0.0%	-52.42%	0.0%	-85.67%	0.0%
Other Long-Term Liabilities	$280.2K	$378.7K
YoY Change	-26.01%
Total Long-Term Liabilities	$430.2K	$528.7K	$315.2K	$315.2K	$2.200M	$2.200M	$0.00	$0.00	$0.00	$0.00	$0.00
YoY Change	-18.63%	67.73%	0.0%	-85.67%	0.0%
Total Liabilities	$5.396M	$3.582M	$1.524M	$1.809M	$3.170M	$2.889M	$30.30K	$11.28K	$0.00	$0.00	$0.00
YoY Change	50.66%	135.0%	-15.75%	-42.93%	9.72%	9434.29%	168.62%

Ownership

Basic Shares Outstanding

Diluted Shares Outstanding

Preferred Stock

Treasury Stock Shares

Stock Issuance & Repurchase

Ownership Data

Concept	2022	2021
Basic Shares Outstanding	7.747M shares	7.630M shares
Diluted Shares Outstanding
Preferred Stock
Treasury Stock Shares

Return On Shareholders' Equity

Book Value

Free Cash Flow

Free Cash Flow YoY

Free Cash Flow Margin

Dividends

Stock Price

Market Cap: $26.497 Thousand

About Rapid Therapeutic Science Laboratories, Inc.

Rapid Therapeutic Science Laboratories, Inc. operates as an early stage emerging biotech company in the legal hemp and cannabis space. The company is headquartered in De Leon, Texas and currently employs 3 full-time employees. The company went IPO on 2013-10-31. The firm is focused on developing potential commercial opportunities which involve the rapid application of therapeutics using inhaler technology. The firm has developed a method of formulating and manufacturing pressurized metered dose inhalers (pMDI) that contain and properly aerosolize proprietary formula of one or more patent pending pharmaceutical-grade cannabinoid compounds. The company has developed and is continuing to develop a series of complementary products in addition to its inhaler. The company is also focusing on manufacturing its own branded MDI under the nhaler brand name.

Industry: Pharmaceutical Preparations Peers: Arch Therapeutics, Inc. NEXGEL, INC. CHEMBIO DIAGNOSTICS, INC. PROCYON CORP ROCKWELL MEDICAL, INC. Sharps Technology Inc. VYCOR MEDICAL INC